Verastem, Inc. (VSTM) · Oct 14, 2026 · Share issuance

Verastem equity offering raises $250M but dilutes shareholders

$250M equity financing — 31.25M shares/warrants at $8.00 per share; ~$250M gross implied

Verastem’s new equity offering should fund VS-7375 development and working capital, but adds roughly 31.25 million shares before expenses.

Verastem is moving from launching AVMAPKI FAKZYNJA CO-PACK in ovarian cancer toward funding a broader oncology pipeline, especially VS-7375, its investigational KRAS G12D inhibitor. The company is running three registration-directed Phase 2 trials for VS-7375 and expects to complete enrollment by the end of 2026, while its confirmatory RAMP 301 ovarian-cancer trial is aimed at a mid-2027 readout.

The financing materially strengthens the near-term funding position. Verastem is selling 30,937,500 common shares plus pre-funded warrants for another 312,503 shares, at approximately $8 per share, implying roughly $250 million of gross proceeds before underwriting costs. 〔0〕 The stated use is continued clinical development, including VS-7375, plus working capital and general corporate purposes.

Offering termAmount
Common shares sold30,937,500
Shares underlying pre-funded warrants312,503
Total potential shares31,250,003
Offering price$8.00 per share-equivalent
Gross proceeds implied by termsApproximately $250 million

The trade-off is substantial equity dilution. Verastem had 90.6 million common shares outstanding as of August 3, 2026; the new securities represent roughly 34% additional shares versus that base, or about 26% of the post-offering share count before other dilution. The pre-funded warrants carry only a $0.0001 exercise price and do not expire, so they function economically much like near-term share issuance.

This addresses a real financing need rather than funding a routine expansion. As of June 30, 2026, Verastem had $136.4 million in cash, cash equivalents and investments and had disclosed substantial doubt about its ability to continue as a going concern without additional capital. The raise therefore buys meaningful runway for commercial operations and the VS-7375 trials, but it does not reduce the clinical or regulatory risk attached to those programs.

Bottom line: The offering is strategically useful because it funds Verastem’s next development phase and relieves a clear capital constraint. It is still a mixed event because shareholders pay for that runway through roughly one-third more potential shares, with no new clinical result in this filing.

What to watch next

Offering expected to close October 15, 2026

Original filing on SEC EDGAR

More Verastem, Inc. news

Verastem equity offering raises $250M but dilutes shareholders | VSTM Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.